Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY:LLY)

819.22 -0.88 (-0.11%)
Streaming Delayed Price Updated: 2:54 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Pfizer Plummets as Key Obesity Drug Candidate Faces Major Setback, Shaking Investor Confidence
New York, NY – September 30, 2025 – Shares of pharmaceutical giant Pfizer (NYSE: PFE) experienced a dramatic decline today, making it one of the market's bottom performers, following an unexpected and... 
Via MarketMinute
Topics Intellectual Property
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing... 
Via MarketMinute
Topics Economy Government World Trade
Why Are Eli Lilly (LLY) Shares Soaring Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 5.5% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the... 
Via StockStory
Topics Government
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Trump's Plan To Lower U.S. Drug Prices Faces Big Test
But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts. 
Via Investor's Business Daily
Topics Government
Global Trade Tensions Unleash Volatility in Stock Futures: A Deep Dive into Tariff-Driven Market Ripples
The global financial markets are currently navigating a tumultuous period, largely driven by an escalating wave of new trade tariffs. As of September 30, 2025, a series of aggressive trade policy... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Why This Beaten-Down GLP-1 Stock Could Be a Steal
There's more to this company than its performance on the stock market this year suggests. 
Via The Motley Fool
Stocks making big moves yesterday: Beyond Meat, The Trade Desk, Guardant Health, PayPal, and Tilray
Check out the companies making headlines yesterday: 
Via StockStory
Topics Cannabis Government
These 2 Top Dividend Stocks Are Finally Rebounding, and There Might Be More Upside Ahead
It's hard to keep these longtime winners down for too long. 
Via The Motley Fool
Topics Artificial Intelligence Government World Trade
3 Growth Stocks to Invest $1,000 Right Now
Market leaders riding secular tailwinds are likely to be profitable long-term investments. 
Via The Motley Fool
Topics Artificial Intelligence
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
Why Guardant Health (GH) Stock Is Trading Up Today
Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 1.6% in the morning session after the U.S. Food and Drug Administration (FDA) approved its Guardant360® CDx blood test as a companion... 
Via StockStory
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
This Is What Whales Are Betting On Eli Lilly
Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE: LLY). And retail traders should know. We noticed this today when the trades showed up on publicly available... 
Via Benzinga
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers. 
Via Benzinga
Topics Government World Trade
1 Unpopular Stock That Deserves Some Love and 2 We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?
The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror. 
Via The Motley Fool
Where Will Recursion Pharmaceuticals Be in 5 Years?
Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry? 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This... 
Via MarketMinute
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
The company continues to improve its pipeline. 
Via The Motley Fool
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Healthcare Sector Reels: A Deep Dive into Thursday's -1.67% Plunge
The healthcare sector experienced a significant downturn on Thursday, September 25, 2025, shedding a notable -1.67% of its value and sending ripples of concern through the broader financial markets.... 
Via MarketMinute
Topics Economy
Amgen Expands US Manufacturing Network Amid New Tariff Policy
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network. 
Via Benzinga
Topics Government World Trade
Your AstraZeneca Medicine Could Be Cheaper As Much As 70%
AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent... 
Via Benzinga
Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs
To gain an edge, this is what you need to know today. 
Via Benzinga
Stock Market Soars: Inflation Data Aligns with Expectations, Igniting Hopes for Continued Fed Easing
New York, NY – September 26, 2025 – U.S. stock market futures, including the Dow, S&P 500, and Nasdaq, registered notable advances today, signaling a robust open after the release of August's inflation... 
Via MarketMinute
Topics Bonds Economy Government
3 Strong-Buy Dividend Growth Stocks
All three of these stocks pay fast-growing dividends. 
Via The Motley Fool
Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst
President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly... 
Via Benzinga
Topics Government World Trade
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer
Eli Lilly secured FDA approval for breast cancer drug Inluriyo and EU clearance for Alzheimer's therapy Kisunla following strong Phase 3 data. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.